The chemoresistant effect of RAS or PIK3CA pathway activation has been described in non-small cell lung cancer and colorectal preclinical models and clinically in patients with cervical cancer; therefore, this may be a true effect. Here, PIK3CA is linked to non-small cell lung carcinoma.